One-Third of Rheumatologists View Bristol Myers Squibb's Sotyktu as Substantial Advance for Psoriatic Arthritis Ahead of March 6 FDA Decision
核心洞察
One in three rheumatologists consider deucravacitinib (Sotyktu) a substantial advance over currently available psoriatic arthritis (搜索) therapies, with nearly half already aware of the upcoming FDA decision.
Physicians estimate roughly one-fifth of their PsA patients would be appropriate candidates for Sotyktu, with most anticipating incorporation into practice within six months of potential approval.
The TYK2 (搜索) inhibitor is expected to compete primarily against oral therapies like JAK (搜索) inhibitors rather than biologics, positioned following inadequate response to TNF (搜索) or IL (搜索) inhibitors.
Bristol Myers Squibb (搜索)'s Sotyktu (deucravacitinib) is generating significant pre-launch interest among U.S. rheumatologists ahead of its March 6, 2026 FDA decision for psoriatic arthritis (搜索) (PsA), with one in three specialists viewing the oral selective TYK2 (搜索) inhibitor as a substantial advance over existing therapies, according to new data from Spherix Global Insights.
The findings, based on a survey of 104 U.S. rheumatologists conducted in January 2026, reveal that nearly half of physicians are already aware of the upcoming FDA decision. Sotyktu emerged as the most frequently cited pipeline therapy in PsA when physicians were asked without prompting, reflecting strong pre-launch visibility ahead of potential commercialization.
Physician Adoption Expectations
If approved, rheumatologists estimate that approximately one-fifth of their PsA patients would be appropriate candidates for Sotyktu, with most physicians anticipating they would incorporate the agent into their practice within six months of launch. The oral TYK2 (搜索) inhibitor is currently approved for psoriasis (搜索) and is under FDA review for the treatment of adults with active psoriatic arthritis (搜索).
When comparing TYK2 (搜索) inhibition with JAK (搜索) inhibitors in PsA, rheumatologists more often associate TYK2 with a potentially improved safety profile, though opinions remain divided on whether efficacy will exceed that of existing JAK inhibitors. This safety perception may prove crucial in a competitive landscape where oral advanced therapies are increasingly scrutinized.
Competitive Positioning and Market Dynamics
Physicians indicate that Sotyktu would most likely displace competing oral therapies—including JAK (搜索) inhibitors such as Pfizer's Xeljanz and AbbVie (搜索)'s Rinvoq, as well as Amgen's Otezla—rather than biologic classes. Most expect the drug to be positioned following inadequate response to TNF (搜索) or IL (搜索) inhibitors, with limited earlier-line use dependent on clinical experience and pricing.
Sotyktu will enter a mature PsA treatment landscape where nearly all patients under rheumatologists' care are pharmacologically treated and the majority are already receiving a biologic or JAK (搜索) inhibitor. As a result, new entrants such as Sotyktu are expected to compete primarily through brand-to-brand share shifts rather than expansion of the treated population. Consistent with this market reality, physicians view oral TYK2 (搜索) inhibition as an incremental addition to the current treatment algorithm rather than a biologic-displacing disruptor.
Partnership Challenges for Bristol Myers Squibb
The launch carries broader implications for Bristol Myers Squibb (搜索) beyond product positioning. Manufacturer partnership data underscore the competitive environment Sotyktu is entering, with significant challenges for BMS in establishing physician relationships. When rheumatologists were asked to rank the top three most respected pharmaceutical partners in PsA, AbbVie (搜索) led decisively, with Amgen, Johnson & Johnson, and UCB (搜索) forming a clear second tier. Bristol Myers Squibb received limited inclusion among rheumatologists' top three most respected partners and ranked lowest overall when weighted by partner standing.
Performance perceptions across key support attributes further highlight this gap. AbbVie (搜索) is consistently viewed as the strongest partner across measures including support of the rheumatology profession, patient services, HUB infrastructure, sales engagement, reimbursement support, and MSL interaction. In contrast, Bristol Myers Squibb (搜索) does not lead on any evaluated partnership metric and is infrequently cited across these dimensions. While BMS maintains an established presence in immunology, including Orencia, the data suggest that it has yet to achieve the same level of partnership recognition in PsA as several of its peers.
Strategic Implications Beyond PsA
The strategic importance of this launch extends beyond PsA. Deucravacitinib is also in clinical development for systemic lupus erythematosus (搜索) (SLE) and Sjögren's disease (搜索), positioning rheumatologists at the center of its potential expansion into broader systemic autoimmune indications. Perceptions established during the PsA launch, including views of the broader TYK2 (搜索) mechanism of action and the manufacturer, may influence receptivity to future line extensions.
The rheumatology debut represents a pivotal opportunity for Bristol Myers Squibb (搜索) to reinforce both clinical differentiation and corporate standing. At the end of the first year and a half on the psoriasis (搜索) market—and at the conclusion of Spherix's Launch Dynamix tracking—dermatologists' initial enthusiasm for Sotyktu's degree of advancement had tempered, and manufacturer launch ratings were rated largely neutral.
As such, the March 6 FDA decision represents more than a potential label expansion. It marks a defining moment for Sotyktu's positioning within rheumatology—and for Bristol Myers Squibb (搜索)'s broader standing in the specialty. Spherix Global Insights will track Sotyktu's entry into the PsA market through its Launch Dynamix service, delivering longitudinal insights into early adoption patterns, brand-to-brand share movement, promotional impact, and evolving physician perceptions during the first 18 months post-launch.